右丙亚胺预防乳腺癌患者蒽环类药物化疗所致心脏毒性的效果和经济性系统综述

发布时间：2018-04-20 21:07

本文选题：右丙亚胺 + 乳腺癌　；参考：《中国新药杂志》2017年11期

【摘要】：目的:对右丙亚胺预防乳腺癌患者化疗所致心脏毒性的效果和经济性进行系统综述。方法:计算机检索Pubmed,Science Direct,The Cochrane Library,EMbase,中国知网数据库、万方数据库和维普中文科技期刊数据库,系统检索国内外公开发表的蒽环类药物联用右丙亚胺治疗乳腺癌的临床研究和经济学研究,并对其进行质量评价。结果:最终纳入9篇文献,包含6篇临床文献(7项随机对照试验)和3篇药物经济学文献。7项随机对照试验中,联用右丙亚胺治疗的患者出现心脏毒性和充血性心力衰竭的概率均显著低于单用蒽环类药物的患者。3篇药物经济学研究中,2篇研究显示相比单用蒽环类药物,蒽环类药物联用右丙亚胺治疗乳腺癌具有经济性,另1篇研究未指出其是否具有经济性。结论:右丙亚胺对于接受蒽环类药物化疗的乳腺癌患者有显著的心脏保护作用。但是,蒽环类药物联用右丙亚胺治疗乳腺癌的药物经济学研究极其有限,需要更多研究来验证。
[Abstract]:Objective: to review the efficacy and economy of dextroimide in preventing cardiotoxicity induced by chemotherapy in breast cancer patients. Methods: computer search was conducted for Pubmedan Science Direct Cochrane Library EMbase, China knowledge Network Database, Wanfang Database and Weipu Chinese Science and Technology Journal Database. The clinical and economic studies of anthracycline combined with dextromine in the treatment of breast cancer at home and abroad were systematically searched and their quality was evaluated. Results: nine articles, including 6 clinical literatures and 7 randomized controlled trials, were included in the study, and 7 randomized controlled trials were included in 3 articles on pharmacoeconomics. The incidence of cardiac toxicity and congestive heart failure in patients treated with dextroimide was significantly lower than that in patients treated with anthracyclines alone. Conclusion: dextroimide has a significant cardioprotective effect on breast cancer patients receiving anthracycline chemotherapy. However, the pharmacoeconomics of anthracycline combined with dexamethimide in the treatment of breast cancer is extremely limited, and more research is needed to verify it.
【作者单位】：中国药科大学国际医药商学院;北京大学中国卫生经济研究中心;
【分类号】：R737.9

【相似文献】